ArticleFrontiers in oncology2026
Prenatal magnetic resonance imaging findings of tuberous sclerosis complex in fetuses.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to characterize the prenatal imaging features of brain and cardiac lesions associated with tuberous sclerosis complex (TSC), with particular focus on fetal magnetic resonance imaging (MRI) findings, and to explore the complementary role of fetal MRI, fetal echocardiography, and genetic testing in prenatal evaluation. Method: This retrospective study analyzed prenatal neurocardiac MRI findings in fetuses diagnosed with TSC or cardiac rhabdomyomas through genetic and/or clinical assessment between 2018 and 2025. Results: Twenty-four fetuses with TSC were included, 23 underwent fetal brain MRI, which revealed abnormalities in 15 cases, including subependymal nodules, cortical dysplasias, and subependymal giant cell astrocytoma. Subependymal nodules appear as hypointense on T2-weighted imaging (T2WI) (14/14, 100%), and the vast majority appear as hyperintense on T1-weighted imaging (T1WI) (12/14, 85.7%), while most show hyperintensity on diffusion-weighted imaging (DWI) (11/14, 78.6%). Cortical dysplasia included cortical tubers and white matter migrational abnormalities. Cortical dysplasia shows hyperintensity on T1WI in all cases (8/8, 100%), hypointensity on T2WI (6/8, 75%), and predominantly hyperintensity on DWI (6/8, 75%). Subependymal giant cell astrocytoma appears hypointense on T2WI and hyperintense on T1WI. According to our research, T1WI was superior to T2WI in demonstrating cortical dysplasia. Intracranial lesions in tuberous sclerosis complex manifest as hyperintense on T1WI (contrasting with the dark background of white matter), a phenomenon often referred to as the "bright spot" sign. Cardiac MRI was performed in 12 of the 24 fetuses. Cardiac rhabdomyomas appear as hyperintense signals on T2WI against the dark background of the myocardium (12/12, 100%), a finding commonly referred to as the "bright spot" sign. Conclusion: The "bright spot" sign on MRI has significant diagnostic value for fetal TSC, particularly for identifying cortical dysplasia and cardiac rhabdomyoma. In cases of suspected TSC or cardiac rhabdomyoma, combining prenatal ultrasound with MRI enhances diagnostic accuracy, facilitating better clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.